Analyst Hints & Ratings — November 16, 2026 — Midday Update — Last 24 Hours (Pacific Time)
Executive Summary
Analyst activity over the past 24 hours skewed broadly bullish, with price target raises and reiterations of Buy-equivalent ratings outnumbering cuts and downgrades. Truist Securities, TD Cowen, Jefferies, and RBC Capital were among the most active firms, collectively covering dozens of names. Key themes driving the session: Nvidia leadership uncertainty sparking a wave of coordinated price target cuts (even as Buy ratings held), SpaceX's Starship milestone triggering broad analyst enthusiasm, and cybersecurity names like CrowdStrike and Palo Alto Networks receiving consistent bullish reaffirmations.
Analyst Action Breakdown
| Action Type | Count | Percentage |
|---|---|---|
| Upgrades | 13 | 9% |
| Downgrades | 12 | 8% |
| PT Raises | 47 | 31% |
| PT Cuts | 35 | 23% |
| Reiterations (no PT change) | 28 | 19% |
| Initiations | 6 | 4% |
| Reinstations | 1 | 1% |
| Other / Mixed | 8 | 5% |
Net Sentiment: Mildly Bullish — PT raises outnumber cuts by a meaningful margin, and upgrades slightly exceed downgrades. However, the volume of cuts — particularly concentrated in Nvidia, Corteva, and several biotech/healthcare names — tempers the overall optimism. The cybersecurity, energy infrastructure, and space sectors leaned clearly bullish; biotech and semiconductors were more mixed.
Top Analyst Calls
🔴 TD Cowen → Nvidia (NVDA) — PT Cut to $200 from $275, maintains Buy
- CEO resignation uncertainty is driving a significant valuation reset, even as the firm holds its bullish long-term thesis.
🔴 UBS → Nvidia (NVDA) — PT Cut to $240 from $300, maintains Buy
- Citing 2028 revenue concerns, UBS joins a multi-firm coordinated pullback on NVDA's near-term target.
🔴 CLSA → Nvidia (NVDA) — Downgraded to Outperform from High-Conviction Outperform, PT cut to $255
- Leadership concerns prompt CLSA to strip its highest-conviction designation from the chip giant.
🟢 Raymond James → SpaceX (SPCX) — Reiterates Strong Buy, $800 PT
- The firm's analyst remains the most bullish on the Street following the latest Starship milestone.
🟢 Bernstein → SpaceX (SPCX) — Reiterates Outperform, $268 PT
- Starship catch milestone reinforces the firm's confidence in SpaceX's long-term reusable rocket thesis.
🟢 Guggenheim → Praxis Precision Medicines (PRAX) — PT Raised to $1,050 from $800, maintains Buy
- One of the largest percentage PT increases of the session, reflecting strong conviction in the biotech's pipeline.
🟢 Raymond James → Lexeo Therapeutics (LXEO) — PT Raised to $42 from $24, maintains Strong Buy
- Positive trial data drives a 75% price target increase, a standout move in the biotech space.
🟢 Evercore ISI → Spotify (SPOT) — Added to Top Picks List, replacing Netflix (NFLX)
- A high-profile rotation signal: Evercore sees more near-term upside in Spotify than Netflix.
🟢 Jefferies → AppLovin (APP) — PT Raised to $500 from $430, maintains Buy
- New model potential drives continued bullish momentum on one of the market's high-momentum names.
🟢 Citi → Box (BOX) — PT Raised to $55 from $40, maintains Buy
- A 37.5% PT increase citing execution strength makes this one of the more aggressive raises of the session.
🔴 Goldman Sachs → Yeti Holdings (YETI) — Downgraded to Neutral from Buy, PT lowered
- Softer demand outlook prompts Goldman to step back from one of its prior consumer discretionary favorites.
🟢 UBS → Nucor (NUE) — Upgraded to Buy from Neutral, PT raised to $307 from $256
- Steel pricing dynamics and improving fundamentals drive a conviction upgrade on the steelmaker.
🟢 Melius → Ingersoll-Rand (IR) — Upgraded to Buy from Hold, PT raised to $113
- Industrial recovery thesis gains traction as Melius turns bullish on the diversified industrial name.
🔴 Stifel → Aardvark Therapeutics (AARD) — PT Cut to $2 from $6, maintains Buy
- FDA uncertainty drives a 67% price target slash, one of the steepest cuts in the biotech space today.
🟢 Truist → Installed Building Products (IBP) — PT Raised to $220 from $180, maintains Buy
- ODG acquisition seen as a meaningful catalyst; RBC also raised its PT on the same name to $215.
Firm Activity Summary
Truist Securities — 12 calls (8 bullish, 3 neutral/hold, 1 bearish)
- BEKE (Buy, PT raise), CON (Buy, PT raise), ABCB (Hold, reiterate), MSFT (Buy, reiterate), JPM (Hold, reiterate), ADIG (PT cut), IBP (Buy, PT raise), TTAN (Buy, reiterate), LINE (Buy, PT cut), ZS (Buy, reiterate), ARMK (Buy, reiterate), IOT (Hold, PT cut)
TD Cowen — 9 calls (6 bullish, 2 bearish, 1 upgrade)
- NTSK (Buy, PT raise), NAVN (Buy, PT raise), OWLT (Buy, PT cut), HALO (Buy, reiterate), CRWD (Buy, reiterate), MIST (PT cut), NVDA (Buy, PT cut), PANW (Buy, reiterate), SPXC (Upgrade to Buy)
Jefferies — 9 calls (6 bullish, 3 bearish)
- BEKE (Buy, PT raise), ABCL (Buy, reiterate), AVEX (Buy, PT cut), APP (Buy, PT raise), TGT (Buy, PT raise), SPOT (Buy, PT raise), YARW (Initiate Buy), AADX (Downgrade to Hold), GEBN/GBERY (Downgrade to Hold), AMRZ (Downgrade to Underperform)
RBC Capital — 8 calls (6 bullish, 1 neutral, 1 bearish)
- IBP (Outperform, PT raise), KNTK (Outperform, PT raise), OHI (Outperform, PT raise), SPCX (Outperform, reiterate), ADUS (Outperform, PT raise), CVS (Outperform, PT cut), CNNE (Downgrade to Sector Perform)
BMO Capital — 5 calls (3 bullish, 2 bearish)
- CEG (Outperform, PT raise), ULTA (Outperform, PT raise), NRG (Market Perform, PT cut), ZBH (Market Perform, PT cut)
UBS — 6 calls (3 bullish, 2 upgrades, 1 bearish initiation)
- NVDA (Buy, PT cut), NUE (Upgrade to Buy), BTU (Upgrade to Buy), VIV (Upgrade to Neutral), OFG (Initiate Sell), FBP (Initiate Neutral)
Guggenheim — 5 calls (4 bullish, 1 mixed)
- PRAX (Buy, PT raise), ABSI (Buy, PT cut), AVBP (Buy, PT cut), JBIO (Buy, PT cut), ZVRA (Buy, PT cut)
Stifel — 8 calls (5 bullish, 2 bearish, 1 downgrade)
- AARD (Buy, PT cut), LXEO (Buy, reiterate), MDB (Buy, reiterate), ZBH (Buy, PT raise), TRGP (Buy, PT raise), ONDS (Buy, PT cut), HMH (Buy, PT cut), SITE (Hold, PT raise), CRM (Buy, reiterate), CDNL (Downgrade to Hold)
Raymond James — 7 calls (6 bullish, 1 bearish)
- QXO (Outperform, reiterate), LXEO (Strong Buy, PT raise), TVRD (Outperform, reiterate), FSS (Outperform, reiterate), DE (Outperform, reiterate), MMSI (Outperform, reiterate), SPCX (Strong Buy, reiterate), DVN (Strong Buy, PT cut)
Mizuho — 7 calls (3 bullish, 3 bearish, 1 upgrade)
- GEMI (Outperform, PT cut), FIGR (Outperform, PT cut), CTVA (Outperform, PT cut), NPCE (Outperform, PT cut), BLTE (Outperform, PT raise), NVDA (Outperform, PT cut), CVI (Upgrade to Neutral)
KeyBanc — 5 calls (2 bullish, 1 neutral, 1 bearish, 1 downgrade)
- NVDA (Sector Weight, reiterate), RVTY (Overweight, reiterate), CTRE (Overweight, PT cut), CTVA (Overweight, PT cut), FMC (Downgrade to Sector Weight)
Cantor Fitzgerald — 5 calls (3 bullish, 1 neutral, 1 bearish)
- LEU (Initiate Overweight), WYFI (Overweight, PT cut), NKE (Neutral, reiterate), PANW (Overweight, reiterate), FLD (Overweight, reiterate), CRWD (Overweight, PT raise)
Susquehanna — 4 calls (3 bullish, 1 bearish)
- AMAT (Positive, reiterate), DLO (Positive, reiterate), MELI (Positive, reiterate), SPCE (Positive, PT cut)
Goldman Sachs — 3 calls (1 bullish, 1 neutral, 1 bearish)
- SPCX (Buy, reiterate), YETI (Downgrade to Neutral), SGI (Reinstate Neutral)
Wedbush — 4 calls (3 bullish, 1 bearish)
- LRMR (Outperform, PT cut), BNTC (Outperform, PT raise), CRSR (Outperform, PT raise), EPRX (Outperform, reiterate)
Piper Sandler — 3 calls (1 bullish, 1 neutral, 1 bearish)
- MIST (PT cut), RBLX (Neutral, reiterate), RITM (Overweight, reiterate)
William Blair — 3 calls (2 bullish, 1 bearish)
- STIM (Initiate Outperform), BILL (Upgrade to Outperform), USAR (Downgrade to Market Perform)
Keefe Bruyette — 3 calls (1 bullish, 1 neutral, 1 bearish)
- JCAP (PT raise), GSHD (PT cut), OTF (PT cut)
JPMorgan — 4 calls (2 bullish, 2 bearish)
- TSLA (Neutral, reiterate), AD (Overweight, PT cut), OVV (Overweight, PT raise), TDS (PT cut)
Telsey — 2 calls (2 bullish)
- WSM (Outperform, PT raise), BBY (Outperform, PT raise)
BofA Securities — 3 calls (3 bullish)
- ED (Buy, PT raise), AWK (Buy, PT raise), BSP (Buy, PT raise)
Citizens — 2 calls (2 bullish)
- IRLA (PT raise), HAE (PT raise)
Wells Fargo — 3 calls (2 bullish, 1 neutral)
- SBH (Equal Weight, PT raise), WES (PT raise), SGHC (Initiate Equal Weight)
Sector Trends
Semiconductors & AI Infrastructure — Cautiously Bullish with Near-Term Headwinds: Nvidia dominated the conversation today, but not in a good way. Multiple firms — TD Cowen, UBS, Mizuho, CLSA, and KeyBanc — all trimmed price targets or reduced conviction ratings, with the common thread being CEO resignation uncertainty and China-related risks. Crucially, most firms maintained Buy-equivalent ratings, suggesting this is a near-term sentiment reset rather than a fundamental thesis change. Bernstein separately flagged that the broader AI stock selloff looks overdone relative to actual datacenter fundamentals, offering a contrarian counterpoint.
Cybersecurity — Consistent Bullish Consensus: CrowdStrike and Palo Alto Networks received multiple bullish reiterations from TD Cowen, Cantor Fitzgerald, and others, with Cantor raising its CrowdStrike PT to $275. The sector shows no signs of analyst fatigue — demand strength and platform consolidation remain the dominant narrative. Zscaler also received a Buy reiteration from Truist.
Space & Defense — SpaceX Steals the Show: The Starship milestone triggered a wave of analyst commentary, with Goldman Sachs, RBC, Bernstein, Raymond James, and Pivotal Research all reiterating bullish stances on SpaceX (SPCX). Price targets range widely — from $225 (RBC) to $800 (Raymond James) — reflecting genuine uncertainty about valuation, but directional conviction is uniformly positive. Virgin Galactic, by contrast, saw a PT cut from Susquehanna on delays, underscoring the divergence within the space sector.
Biotech & Healthcare — Highly Bifurcated: The biotech space saw some of the most dramatic moves in both directions. Praxis Precision Medicines received a massive PT raise to $1,050, and Lexeo Therapeutics jumped to a $42 target on trial data. On the other side, Aardvark Therapeutics was slashed to $2 on FDA uncertainty, Milestone Pharmaceuticals was cut by both TD Cowen and Piper Sandler on weak sales data, and Zevra Therapeutics was trimmed on an EU setback. FDA catalysts and clinical data remain the primary swing factors.
Market Implications
The most significant signal from today's analyst activity is the coordinated but contained Nvidia reset. Five separate firms cut price targets on NVDA, yet virtually all maintained Buy-equivalent ratings. This is the market's way of saying: the long-term AI infrastructure thesis remains intact, but the near-term risk premium has risen meaningfully due to leadership uncertainty. Investors should watch whether the CEO situation resolves quickly — if it does, these PT cuts could reverse just as fast.
The Evercore rotation from Netflix to Spotify as a top pick is worth noting as a consumer discretionary signal. It suggests analysts see Spotify's monetization story (ad-supported tier growth, podcast, audiobooks) as a more compelling near-term catalyst than Netflix's already-priced-in subscriber narrative. Jefferies simultaneously raised its Spotify PT, adding weight to the bullish case.
The industrial recovery theme is quietly gaining traction. Melius upgraded Ingersoll-Rand, TD Cowen upgraded SPX Technologies on data center demand, and multiple firms raised targets on energy infrastructure names like Targa Resources, Kinetik, and Western Midstream. This suggests analysts are beginning to price in a broader capex cycle recovery — particularly where industrial names intersect with AI-driven power and data center buildout.
Key Takeaways
- 🔴 Nvidia (NVDA) — Five firms cut price targets (TD Cowen to $200, UBS to $240, Mizuho to $220, CLSA to $255, KeyBanc at $155) on CEO uncertainty; all maintain bullish ratings, signaling a sentiment — not thesis — shift.
- 🟢 SpaceX (SPCX) — Five firms reiterated bullish stances post-Starship milestone; Raymond James holds the Street-high target at $800, while RBC sits at $225 — the wide range reflects genuine valuation debate.
- 🟢 Evercore ISI — Dropped Netflix from its top picks list and added Spotify, a high-conviction rotation call that signals where the firm sees the best near-term risk/reward in media.
- 🟢 Praxis Precision Medicines (PRAX) — Guggenheim raised PT to $1,050 from $800, one of the largest absolute PT increases of the session.
- 🟢 Lexeo Therapeutics (LXEO) — Raymond James raised PT to $42 from $24 on trial data; Stifel separately reiterated Buy at $17, showing split conviction levels on the same catalyst.
- 🟢 AppLovin (APP) — Jefferies raised PT to $500 from $430, continuing a streak of bullish momentum calls on the ad-tech platform.
- 🟢 Installed Building Products (IBP) — Both Truist (to $220) and RBC (to $215) raised targets on the ODG acquisition, a rare same-day consensus PT lift.
- 🔴 Aardvark Therapeutics (AARD) — Stifel slashed PT to $2 from $6 on FDA uncertainty; a 67% cut while maintaining Buy raises questions about conviction.
- 🟢 Nucor (NUE) — UBS upgraded to Buy and raised PT to $307 from $256 on steel pricing dynamics — a notable sector call.
- 🔴 Yeti Holdings (YETI) — Goldman Sachs downgraded to Neutral from Buy on softer demand; a meaningful sentiment shift from a top-tier firm.
- 🟢 Citi → Box (BOX) — PT raised to $55 from $40 (37.5% increase) on execution strength; one of the more aggressive raises outside of biotech.
- 🟢 Melius → Ingersoll-Rand (IR) — Upgraded to Buy from Hold with PT of $113, adding to the emerging industrial recovery narrative.
- 🔴 Corteva (CTVA) — Both KeyBanc (to $14) and Mizuho (to $13) cut targets independently, signaling growing concern about the ag-chem company's earnings trajectory.
- 🔴 Milestone Pharmaceuticals (MIST) — Both TD Cowen (to $5) and Piper Sandler (to $3) cut targets on weak sales data; a clear negative consensus forming.
- 🟢 William Blair → Bill.com (BILL) — Upgraded to Outperform from Market Perform on monetization outlook; a conviction call from a firm that had been on the sidelines.
- 🔴 Macquarie → Bilibili (BILI) — Downgraded to Neutral from Outperform on ad budget shift concerns; a bearish signal for Chinese digital media.
- 🟢 Cantor Fitzgerald → Centrus Energy (LEU) — Initiated with Overweight; a new bullish voice on the nuclear fuel play.
- 🔴 Freedom Broker → Real Brokerage (REAX) — PT slashed to $25 from $40 (37.5% cut) on softer real estate trends; one of the steepest percentage cuts of the session outside biotech.
- 🟢 Telsey → Williams-Sonoma (WSM) & Best Buy (BBY) — Raised targets on both (WSM to $285, BBY to $110), suggesting improving sentiment on higher-end and big-box retail heading into the holiday season.
- 🟢 UBS → Nucor (NUE) + Peabody Energy (BTU) — Two upgrades in the materials/energy space in one session signals UBS is rotating toward value and cyclicals.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/